검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cyclophosphamide and Fludarabine (Lymphodepleting Therapy, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)) Janssen Scientific Affairs, LLC·Multiple Myeloma ORR 67% |
|---|---|
Overview Program | Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) |
Overview Company | Janssen Scientific Affairs, LLC |
Overview Modality | ANTIBODY |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting RCC-associated minor histocompatibility antigen |
MoA Biomarker | biomarkers in chronic lymphocytic leukemia (CLL) have been useful in predicting response to chemoimmunotherap |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Efficacy and Safety of Bendamustine Versus Fludarabine and Cyclophosphamide as Lymphodepleting Regimens for CAR-T Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis.. Chimeric antigen receptor T-cell (CAR-T) therapy has become an established treatment for hematological malignancies. Lymphodepleting (LD) chemotherapy is a preparatory step that facilitates CAR-T cell expans… |
Toxicology CRS | 60.2% |
Clinical Primary efficacy | ORR 67% |
Clinical ORR | 67% |
Clinical Result source | ClinicalTrials.gov NCT03704298 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cyclophosphamide and Fludarabine (Lymphodepleting Therapy, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)) Janssen Scientific Affairs, LLC·Multiple Myeloma ORR 67% |
|---|---|
Overview Program | Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) |
Overview Company | Janssen Scientific Affairs, LLC |
Overview Modality | ANTIBODY |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting RCC-associated minor histocompatibility antigen |
MoA Biomarker | biomarkers in chronic lymphocytic leukemia (CLL) have been useful in predicting response to chemoimmunotherap |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Efficacy and Safety of Bendamustine Versus Fludarabine and Cyclophosphamide as Lymphodepleting Regimens for CAR-T Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis.. Chimeric antigen receptor T-cell (CAR-T) therapy has become an established treatment for hematological malignancies. Lymphodepleting (LD) chemotherapy is a preparatory step that facilitates CAR-T cell expans… |
Toxicology CRS | 60.2% |
Clinical Primary efficacy | ORR 67% |
Clinical ORR | 67% |
Clinical Result source | ClinicalTrials.gov NCT03704298 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교